There continues to be rapid advancement in our understanding of the pathogenesis of immune-mediated kidney disease. This progress has culminated in the development of multiple therapeutic agents that have consistently improved renal and patient outcomes. The focus of this review is to discuss these recent advancements in immune-mediated kidney disease via the lens of direct and indirect immune-mediated mechanisms. In the direct immune-mediated disease, recently described antigens in anti-glomerular basement membrane (GBM) disease and membranous nephropathy are discussed, along with new therapeutic regimens in membranous nephropathy and focal segmental glomerulosclerosis. From an indirect immune-mediated disease standpoint, recent pivotal trials in antineutrophil cytoplasmic antibody vasculitis, lupus nephritis, and IgA nephropathy are examined from a real-world practice perspective. New molecular pathways in various disorders of alternate complement pathway are described, which in turn have led to development of various experimental therapies. In addition, pivotal and ongoing therapeutic trials in the aforementioned diseases are presented.
Keywords: Alternative complement pathway; C3 glomerulopathy (C3G); IgA nephropathy (IgAN); anti-GBM disease; antibodies; atypical hemolytic uremic syndrome (aHUS); autoantibodies; glomerular basement membrane (GBM); glomerulonephritis; immune complex deposition; immune-mediated kidney disease; immunosuppression; lupus nephritis (LN); pathogenesis; review.
Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.